TABLE 3.
Inhibitory activities of conjugated peptides and control peptides against HIV-1 T20- and T2635-resistant strains
| Virus description | Mean IC50 ± SD (nM)a |
|||
|---|---|---|---|---|
| WQ | WQ-IDL | MT-WQ-IDL | T20 | |
| T20-resistant strains | ||||
| Wild type | 160.8 ± 20.0 | 6.8 ± 1.9 | 2.2 ± 1.0 | 55.3 ± 2.6 |
| V38A | 433.1 ± 67.0 | 22.0 ± 2.9 | 4.4 ± 1.0 | >500 |
| V38A N42D | 34.8 ± 9.1 | 2.9 ± 0.2 | 1.0 ± 0.2 | >500 |
| V38E N42S | 65.2 ± 2.3 | 1.6 ± 0.6 | 0.3 ± 0.3 | >500 |
| V38A N42T | 118.0 ± 13.0 | 7.5 ± 2.4 | 0.1 ± 0.1 | >500 |
| T2635-resistant strains | ||||
| Wild type | 195.1 ± 20.0 | 17.8 ± 1.9 | 3.9 ± 1.0 | 98.9 ± 2.6 |
| A6V | 303.4 ± 67.0 | 18.3 ± 2.9 | 6.4 ± 1.0 | 66.2 ± 5.6 |
| Q66R | 434.8 ± 9.1 | 12.9 ± 0.2 | 6.0 ± 0.2 | >500 |
| Q79E | 965.2 ± 2.3 | 51.6 ± 0.6 | 11.3 ± 0.3 | >500 |
| K90E | 218.4 ± 13.0 | 8.5 ± 2.4 | 1.1 ± 0.1 | >500 |
| Q79E N126K | 1128.4 ± 33.0 | 61.4 ± 1.6 | 9.2 ± 1.3 | >500 |
a
IC50 data were derived from the results of three independent experiments.